Human PlGF Antibody

Catalog #: MAB11197 Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
MAB11197-100
MAB11197-SP

VEGFR1/Flt-1 Binding to PlGF is Blocked by Human PlGF Antibody

1 Image

All PlGF Antibodies

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human PlGF Antibody Summary

Species Reactivity

Human

Specificity

Detects human PIG-1,2,3 and 4 in direct ELISAs.

Source

Monoclonal Mouse IgG_2A Clone # 1038863

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

E. coli-derived human PlGF
Ala21-Arg149
Accession # P49763

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Label

Unconjugated

Applications

Recommended Concentration

Sample

Neutralization

In a functional ELISA binding assay, 0.150-1.80 ug/mL of this antibody will block the binding of 100 ng/mL of recombinant human VEGFR1/Flt-1 Fc Chimera (Catalog # 3516-FL) to immobilized recombinant human PLGF (Catalog # 264-PGB) coat at 0.5 ug/mL (100 uL/well).

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Neutralization

View Larger

VEGFR1/Flt-1 Binding to PlGF is Blocked by Human PlGF Antibody In a functional ELISA, 0.150-1.80 µg/mL of this antibody will block 50% of the binding of 100 ng/mL Recombinant Human VEGFR1/Flt-1 Fc Chimera, aa 27-328 (3516-FL) to Recombinant Human PlGF (264-PGB) immobilized at 0.5 μg/mL (100 µL/well)

Reconstitution Calculator

Preparation and Storage

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: PlGF

Placenta Growth Factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines (1, 2). Alternative splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively (1, 2). Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus (1). Human PlGF-1 shares 56%, 55%, 74% and 95% aa identity with the comparable isoform of mouse, rat, canine, and equine PlGF, respectively. PlGF is mainly found as variably glycosylated, secreted, 55-60 kDa disulfide linked homodimers (3). Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes, and some endothelial cells (1, 4-6). Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia (7). However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia (8). PlGF binds and signals through VEGF R1/Flt-1 but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis (1, 4, 8, 9). However, PlGF (especially PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2 (3, 4). PlGF-2, but not PLGF-1, shows heparin-dependent binding of Neuropilin (Npn)-1 and Npn-2 (10, 11). PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound, bone fracture, and cardiac repair, but also contribute to inflammation in active sickle cell disease and atherosclerosis (5, 6, 8, 12-15). PlGF can also inhibit TIMP3 expression in the spleen, leading to immune triggering of hypertension (16).

References

Hauser, S. and H.A. Weich (1993) Growth Factors 9:259.
Maglione, D. et al. (1993) Oncogene 8:925.
Eriksson, A. et al. (2002) Cancer Cell 1:99.
Ribatti, D. (2008) Angiogenesis 11:215.
Oura, H. et al. (2003) Blood 101:560.
Roncal, C. et al. (2010) Cardiovasc. Res. 86:29.
Levine, R.J. et al. (2004) N. Engl. J. Med. 350:672.
Carmeliet, P. et al. (2001) Nat. Med. 7:575.
Autiero, M. et al. (2003) Nat. Med. 9:936.
Migdal, M. et al. (1998) J. Biol. Chem. 273:22272.
Cheng, L. et al. (2004) J. Biol. Chem. 279:30654.
Perelman, N. et al. (2003) Blood 102:1506.
Cianfarani, F. et al. (2006) Am. J. Pathol. 169:1167.
Maes, C. et al. (2006) J. Clin. Invest. 116:1230.
Iwasaki, H. et al. (2011) PLoS One 6:e24872.
Carnevale, D. et al. (2014) Immunity 41:737.

Long Name

Placenta Growth Factor

Entrez Gene IDs

5228 (Human); 18654 (Mouse)

Alternate Names

D12S1900; PGF; PGFL; placenta growth factor; placental growth factor; placental growth factor, vascular endothelial growth factor-related protein; PlGF; PlGF-2; PLGFplacental growth factor-like; SHGC-10760